Regulus Therapeutics’ (RGLS) “Buy” Rating Reaffirmed at HC Wainwright

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $10.00 price target on the biopharmaceutical company’s stock.

Several other brokerages have also recently weighed in on RGLS. Oppenheimer reiterated an “outperform” rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research note on Wednesday, August 14th. StockNews.com raised Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Regulus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

Regulus Therapeutics Trading Up 10.6 %

Shares of NASDAQ RGLS opened at $1.56 on Monday. The firm has a market cap of $102.13 million, a P/E ratio of -1.46 and a beta of 1.63. The business’s 50 day moving average is $1.55 and its 200-day moving average is $1.82. Regulus Therapeutics has a 1-year low of $1.08 and a 1-year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Analysts forecast that Regulus Therapeutics will post -0.8 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Creative Planning bought a new stake in shares of Regulus Therapeutics in the 3rd quarter valued at about $26,000. SG Americas Securities LLC bought a new position in Regulus Therapeutics during the 3rd quarter worth approximately $33,000. Rhumbline Advisers acquired a new position in shares of Regulus Therapeutics in the 2nd quarter worth approximately $136,000. Tyche Wealth Partners LLC increased its position in shares of Regulus Therapeutics by 920.6% during the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock worth $167,000 after buying an additional 95,694 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Regulus Therapeutics by 56.4% during the second quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 42,600 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.